Skip to main content
NewslettersWatchlist

Morphic Holding Inc(MORF-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low56.97
Day High57.00
Open:56.98
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Motley Fool
Americans Are Flying; Airline Stocks Are Not
Barchart
Stock Index Futures Inch Higher Ahead of Powellโ€™s Testimony
Barchart
Broader Market Settles Higher on Chip Stock Strength
Barchart
Chip Stocks Support Overall Stock Market
Barchart
S&P 500 and Nasdaq 100 Post Record Highs as Chip Stocks Climb
SYNDTGAM
Eli Lilly to buy bowel disease drug developer Morphic for US$3.2-billion
Barchart
Stocks Set for Muted Open as Investors Await U.S. Inflation Data and Big Bank Earnings, Powellโ€™s Testimony on Tap
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
PR Newswire
MORF INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF)
Barchart
Stocks Recover Early Losses on Soft Landing Optimism for the U.S. Economy
Barchart
Stocks Mixed as Global Bond Yields Climb
Barchart
Markets Today: Stocks Lower on Concern about Hawkish Global Central Banks
Motley Fool
3 Biotech Buyout Targets to Watch
Globe Newswire
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022
Globe Newswire
Morphic to Present at 2022 Jefferies Global Healthcare Conference
Globe Newswire
Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs
Globe Newswire
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022
Globe Newswire
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
Globe Newswire
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis
Globe Newswire
Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
Globe Newswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021

Profile

Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.